61
Participants
Start Date
January 31, 2005
Primary Completion Date
November 30, 2008
Study Completion Date
November 30, 2011
FCCam
After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
University of Cologne, Cologne
University of Cologne
OTHER
MedacSchering Onkologie
UNKNOWN
German CLL Study Group
OTHER